Effect of selective @entity750 reuptake inhibitors on platelet activation: can they prevent acute XXXX ?

@entity1 @entity308 @entity1423 @entity3002 @entity3756 @entity2339 @entity750 @entity583 @entity65
In recent years a large body of evidence from several longitudinal studies has emerged suggesting that @entity308 is an independent risk factor for @entity65 ( @entity65 ) and that the association between @entity308 and increased @entity65 risk is not merely due to negative mood-driven behavior related with @entity308 . Even though the underlying mechanisms are not well understood, several hypotheses and explanations have been proposed such as increased activation of the @entity2339 , @entity3002 , or @entity1423 . Platelet function abnormalities, including increased platelet reactivity, may predispose @entity1 with @entity308 to clotting diatheses and may explain their vulnerability to @entity65 . @entity750 secreted by platelets induces both @entity1423 and coronary vasoconstriction. Even though @entity750 itself is only a weak platelet agonist, it markedly enhances platelet reactions to a variety of other agonists. Several studies have shown that selective @entity750 reuptake inhibitors (SSRIs) reduce platelet and whole blood @entity750 concentrations after repeated doses, and could therefore exert an inhibitory effect on platelet activation. For that reason, it was hypothesized that SSRIs could have a protective effect against @entity583 ( @entity583 ). Results from three currently available epidemiological studies assessing the risk of @entity583 in @entity1 treated with antidepressants, including SSRIs, are controversial with respect to a potential beneficial effect of SSRIs on @entity65 risk in @entity308 @entity1 . However, there is evidence that exposure to SSRIs does not substantially increase the risk of @entity65 in @entity1 . A recent randomized, double-blind, placebo-controlled, multicenter trial that evaluated the safety and efficacy of the SSRI sertraline in @entity1 with @entity308 and @entity583 suggested that @entity3756 is well tolerated and effective. Further epidemiological studies or longer-term clinical trials may shed more light on this issue, and answer the question conclusively, whether the effect of SSRIs on platelets or another mechanism translates into a decreased risk of @entity65 in @entity308 @entity1 .
